Caris Life Sciences

Empowering Clinicians with Caris Assure. This groundbreaking assay helps guide more targeted and confident treatment decision. Discover how Caris Assure’ advanced profiling can help improve patient outcomes and sets a new benchmark in liquid biopsy technology. Caris Chief Scientific Officer Milan Radovich, PhD, explains how Caris Assure sets a new standard in liquid biopsy profiling. Learn more: https://lnkd.in/gZm92Zdg

New insights on renal cell carcinoma (RCC) could transform treatment. A study by Caris and partners within the Caris Precision Oncology Alliance highlights how AI analysis of metastatic RCC can guide personalized therapy. Findings suggest that tailoring immunotherapy and treatment with mTOR inhibitors based on tumor molecular profile may improve patient outcomes and could extend cancer-free survival. Caris Life Sciences contributors Daniel Magee, Ph.D., and Andrew Elliott, Ph.D. provide insights into this research.

At the Caris Blood Lab in Phoenix, we were honored to host key Arizona state and federal officials alongside our dedicated team to discuss biomarker legislation and recent advancements in cancer care. While 15 states, including Arizona and Texas, have passed laws for biomarker testing coverage, more work still needs to be done. Caris is committed to improving access to biomarker testing through ongoing collaboration and advocacy. Learn more: https://lnkd.in/ghZHwm-4 Charles Lucking Laurin Hendrix Stephanie Stahl Hamilton Walt Blackman John Kavanagh Janae Shamp Shawnna LM Bolick Michael Madden Greg Stanton David Schweikert David Spetzler Matthew Oberley, MD, PhD Russ Denton Robert (Bobby) Hill Mike Sullivan Rob Hahn-Lowry

Caris announced a multi-year research collaboration with ECOG-ACRIN Cancer Research Group. The first collaborative project is an interrogation of the TAILORx breast cancer trial, enabling discovery for risk stratification, prediction of recurrence and racial disparity drivers. “I’m excited to build on the trial’s initial findings which prevented millions of women with early breast cancer from having to endure toxic treatments, to continue discerning valuable insights related to long term recurrence risk and to identify even more women who may benefit from more efficient treatment options,” said George Sledge, Jr., MD, EVP and Chief Medical Officer of Caris. Learn more: https://lnkd.in/gi5GGbsb

Does precision oncology play a role in reducing health disparities? A multi-institutional study led by Karmanos Cancer Institute investigates health disparities in a diverse cohort of over 12,000 patients who underwent molecular tumor profiling. Learn more: https://lnkd.in/ghj5iycp

The “Mom Rule” is Caris Life Sciences’ guiding principle, emphasizing the importance of treating every patient as if they were your own mother. Driven by our commitment to helping patients, we are paving the way for personalized care and helping improve outcomes. Learn more about our culture of compassion and scientific excellence from Caris President David Spetzler: https://lnkd.in/gA4XqwnT

Meet Jeanine Cervoni, a breast cancer survivor and advocate for awareness. With the support of Caris Life Sciences' innovative testing, she gained a deeper understanding of her cancer and made informed treatment choices. Her journey highlights the importance of personalized care. We observe Breast Cancer Awareness Month this October and advocate for tailored treatment solutions. Learn more: https://lnkd.in/gWN_f5MG   #BreastCancerAwarenessMonth #PrecisionMedicine #MolecularProfiling

Can RNA transcriptional subtyping (TS) help predict outcomes in #pancreaticcancer? A study of more than 8,700 patients shows that the strongly basal (SB) subtype is a strong independent predictor of worse outcome irrespective of mutant KRAS allele & chemotherapy regimen. TS may be useful for prognostication in clinical care and risk stratification in clinical trials. Learn more: https://lnkd.in/gM76nUxy #CancerResearch #PrecisionMedicine

Discover the future of cancer care during the College of American Pathologists (CAP) Annual Meeting. Stop by booth 234 to connect with Caris and explore advanced molecular profiling solutions. Take advantage of the opportunity to network during #CAP24.

Discover the power of Caris Assure! Our liquid biopsy assay, Caris Assure, provides unparalleled molecular insights from a minimally invasive blood sample. With its pan-cancer coverage, this revolutionary assay empowers clinicians to make targeted treatment decisions confidently. Don't wait any longer—discover how Caris Assure can help: https://lnkd.in/gZm92Zdg #LiquidBiopsy #PrecisionMedicine #CarisAssure